NCT02032433View on ClinicalTrials.gov

Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

570

Participants

Timeline

Start Date

January 29, 2014

Primary Completion Date

January 25, 2017

Study Completion Date

January 31, 2017

Conditions
Opioid Use Disorder
Interventions
DRUG

Extended-Release Naltrexone

Extended-Release Naltrexone (Vivitrol®)

DRUG

Buprenorphine-Naloxone

Buprenorphine-Naloxone (Suboxone®)

Trial Locations (8)

10016

Bellevue Hospital Center, New York

20853

Avery Road Treatment Center, Rockville

32201

Gateway Community Services, Inc., Jacksonville

43207

Maryhaven, Columbus

87108

Turquoise Lodge Hospital, Albuquerque

91356

Tarzana Treatment Centers, Tarzana

98134

Evergreen Treatment Services, Seattle

02720

Stanley Street Treatment and Resources, Fall River

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

The Emmes Company, LLC

INDUSTRY

lead

NYU Langone Health

OTHER

NCT02032433 - Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment | Biotech Hunter | Biotech Hunter